MOH — authorised 14 December 2020
- Marketing authorisation holder: ALMIRALL
- Status: likely_approved
MOH authorised Klisyri on 14 December 2020
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 14 December 2020.
ALMIRALL holds the Israeli marketing authorisation.